Achaogen, Inc. (AKAO) Given Average Recommendation of “Buy” by Analysts

Shares of Achaogen, Inc. (NASDAQ:AKAO) have earned an average rating of “Buy” from the thirteen analysts that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and nine have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $25.64.

Several equities research analysts have recently issued reports on AKAO shares. Mizuho reissued a “buy” rating and issued a $28.00 price objective on shares of Achaogen in a research report on Thursday, September 28th. Stifel Nicolaus decreased their target price on shares of Achaogen from $30.00 to $27.00 and set a “buy” rating for the company in a research note on Thursday, November 9th. HC Wainwright restated a “buy” rating and issued a $25.00 target price on shares of Achaogen in a research note on Thursday, November 9th. Guggenheim initiated coverage on shares of Achaogen in a research note on Tuesday, October 24th. They issued a “buy” rating and a $17.00 target price for the company. Finally, Zacks Investment Research upgraded shares of Achaogen from a “sell” rating to a “hold” rating in a research note on Monday, December 11th.

Achaogen (NASDAQ AKAO) opened at $11.05 on Monday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 6.99 and a current ratio of 6.99. Achaogen has a 52-week low of $10.24 and a 52-week high of $27.79.

Achaogen (NASDAQ:AKAO) last posted its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.13). Achaogen had a negative net margin of 593.61% and a negative return on equity of 80.44%. The firm had revenue of $0.58 million during the quarter, compared to analyst estimates of $2.09 million. During the same period in the prior year, the firm earned ($0.41) EPS. The business’s quarterly revenue was down 96.4% on a year-over-year basis. research analysts forecast that Achaogen will post -3.06 EPS for the current fiscal year.

In other news, COO Blake Wise sold 3,576 shares of the company’s stock in a transaction on Tuesday, September 26th. The shares were sold at an average price of $15.99, for a total value of $57,180.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 8.36% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Marcus Capital LLC bought a new position in Achaogen during the 2nd quarter valued at $1,769,000. Artal Group S.A. increased its stake in Achaogen by 25.0% during the 3rd quarter. Artal Group S.A. now owns 250,000 shares of the biopharmaceutical company’s stock valued at $3,988,000 after buying an additional 50,000 shares during the period. Bank of New York Mellon Corp increased its stake in Achaogen by 68.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 191,670 shares of the biopharmaceutical company’s stock valued at $4,165,000 after buying an additional 77,887 shares during the period. TimesSquare Capital Management LLC increased its stake in Achaogen by 106.7% during the 2nd quarter. TimesSquare Capital Management LLC now owns 1,088,300 shares of the biopharmaceutical company’s stock valued at $23,649,000 after buying an additional 561,700 shares during the period. Finally, Schwab Charles Investment Management Inc. acquired a new position in Achaogen during the 2nd quarter valued at about $1,050,000. Hedge funds and other institutional investors own 85.81% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This report was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this report on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The correct version of this report can be viewed at https://sportsperspectives.com/2017/12/18/achaogen-inc-akao-given-average-recommendation-of-buy-by-analysts.html.

Achaogen Company Profile

Achaogen, Inc is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).

Analyst Recommendations for Achaogen (NASDAQ:AKAO)

Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply